Physician profile
William E Richheimer
NPI 1376583575
$3,282.97
in general payments reported to CMS, 2019-2025
22 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $85.31 · 2021: $237 · 2022: $363 · 2023: $637 · 2024: $914 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Entertainment: $88.18 · Honoraria: $25.59 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.85 |
| Entertainment | $88.18 |
| Honoraria | $25.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,111.31 | 2019-2025 | Clareon, Wavelight Refractive Suite, Rocklatan |
| Rxsight INC | $356.08 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $348.09 | 2022-2025 | |
| Glaukos Corporation | $298.08 | 2019-2025 | Idose, Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Ocular Therapeutix, INC. | $182.64 | 2023-2025 | Dextenza |
| Staar Surgical Company | $171.18 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $144.22 | 2021-2025 | |
| Allergan, INC. | $106.30 | 2019-2021 | |
| Optos, INC. | $88.18 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $75.00 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $69.35 | 2022-2024 | Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $68.00 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $37.72 | 2025 | Iheezo, Triesence |
| Kala Pharmaceuticals, INC. | $33.81 | 2020-2021 | |
| Oyster Point Pharma, INC. | $28.94 | 2023 | Tyrvaya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.85 | 2023 | |
| Sight Sciences, INC. | $25.99 | 2022 | |
| Carl Zeiss Meditec, INC. | $25.00 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.36 | 2021 | |
| Alimera Sciences, INC. | $21.77 | 2023 | Iluvien |
| Sun Pharmaceutical Industries INC. | $19.73 | 2024 | |
| Dompe US, INC. | $19.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Richheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.